Skip to main content
David Vesole, MD, Oncology, Hackensack, NJ, Hackensack Meridian Health Hackensack University Medical Center

DavidH.VesoleMDPhD

Oncology • Hackensack, NJ

Co-Chief, Myeloma Division; Director, Myeloma Research, John Theurer Cancer Center; Director, Myeloma Program, Medstar Georgetown University Hospital

Request Appointment

Overview of Dr. Vesole

David H. Vesole, MD, PhD, FACP
Co-Director, Myeloma Division; Director, Myeloma Research
John Theurer Cancer Center at Hackensack University Medical Center
Professor of Medicine, Georgetown University
Director, Multiple Myeloma Program

David H. Vesole completed a medical degree at Northwestern University and a doctorate in immunology and microbiology at the Medical University of South Carolina. His postdoctoral training included a residency in internal medicine and a fellowship in Hematology and Oncology at University of Iowa Hospitals and Clinics. Dr. Vesole is Co-Director, Myeloma Division and Director, Myeloma research at the John Theurer Cancer Center at Hackensack University Medical Center. He is Professor of Medicine at Georgetown University where he is Director, Myeloma Program. Dr. Vesole previously was the Director, BMT Program Loyola University in Maywood, IL, an attending physician at St. Vincent's Comprehensive Cancer Center in New York and Professor of Medicine and Clinical Director of the Blood and Marrow Transplant Program at the Medical College of Wisconsin in Milwaukee, WI.

Board certified in medical oncology and hematology and a Fellow of the American College of Physicians, Dr. Vesole is active in several professional organizations, including the American Society for Blood and Marrow Transplantation, the American Society of Clinical Oncology and the American Society of Hematology. He previously served as Co-chair of the Eastern Cooperative Oncology Group Myeloma Committee and the Center for International Blood and Marrow Transplant Research (CIBMTR) Plasma Cell Disorder Committee. He was on the Nominating Committee for the CIBMTR. He is a Foundation for the Accreditation of Cellular Therapy (FACT) inspector and serves on the Clinical Standards, Accreditation and Data Management Task Force Committees for FACT. He is a member of the International Myeloma Working Group.

Education & Training

  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1987 - 1990
  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1984 - 1987
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 1984

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2009 - 2025
  • NY State Medical License
    NY State Medical License 2005 - 2025
  • MD State Medical License
    MD State Medical License 2018 - 2025
  • DC State Medical License
    DC State Medical License 2012 - 2024
  • IL State Medical License
    IL State Medical License 1985 - 2011
  • WI State Medical License
    WI State Medical License 1996 - 2009
  • IA State Medical License
    IA State Medical License 1984 - 2005
  • American Board of Internal Medicine Internal Medicine
  • ABIMHematology
  • ABIMMedical Oncology
  • Join now to see all

Awards, Honors, & Recognition

  • Board Member Leukemia Lymphoma Society, New York
  • Inside Jersey Magazine Top Doctors Castle Connolly, 2010-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2010-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
    Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
  • Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...  
    Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature

Abstracts/Posters

  • Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Mu...
    David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
    David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
    David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Recent Advancements and Future Directions in Frontline Treatment of Multiple Myeloma
    Recent Advancements and Future Directions in Frontline Treatment of Multiple MyelomaJuly 11th, 2022
  • John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual Conference
    John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual ConferenceDecember 9th, 2021
  • John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100
    John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100August 4th, 2017
  • Join now to see all

Committees

  • Member, ASCO Clinical Practice Guidelines Committee 2015 - Present
  • Nominating Committee, American Society of Blood and Marrow Transplant 2015 - Present
  • Member, ASCO Plasma Cell Educational Committee 2015 - Present
  • Data Audit Committee, Federation for The Accreditation of Cellular Therapy 2014 - Present
  • Accreditation Committee, Federation for The Accreditation of Cellular Therapy
  • Clinical Standards Committee, Federation for The Accreditation of Cellular Therapy
  • Scientific Advisory Committee, International Myeloma Foundation
  • Myeloma Committee, Blood and Marrow Transplant Clinical Trials Network

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    AmeriHealth Direct POS
    Amerihealth HMO
    AmeriHealth PPO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS PPO
    First Health PPO
    GHI PPO
    Great West PPO
    Horizon BCBS Direct Access
    Horizon BCBS HMO
    Horizon BCBS POS
    Horizon BCBS PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. David Vesole, Dr. David Vesole, MD, Dr. D Vesole, Dr. David H. Vesole